J
Johan Lindholm
Researcher at Karolinska University Hospital
Publications - 59
Citations - 3928
Johan Lindholm is an academic researcher from Karolinska University Hospital. The author has contributed to research in topics: Cancer & Epidermoid carcinoma. The author has an hindex of 25, co-authored 59 publications receiving 3767 citations. Previous affiliations of Johan Lindholm include Karolinska Institutet.
Papers
More filters
Journal ArticleDOI
Nuclear DNA content, proliferating‐cell nuclear antigen (PCNA) and p53 immunostaining in predicting progression of laryngeal cancer in situ lesions
TL;DR: By combining the results from the analyses of DNA, PCNA and p53 in a prognostic index for each individual case, this work correctly classified 82% of the lesions as progressors or non‐progressors.
Journal ArticleDOI
Predictive value of malignancy grading systems, DNA content, p53, and angiogenesis for stage I tongue carcinomas.
TL;DR: Both Jakobsson's malignancy grading system and p53 immunoreactivity proved to be useful predictors of regional recurrence in a Cox multivariate regression analysis.
Journal ArticleDOI
The importance of rectal cancer MRI protocols on iInterpretation accuracy
Chikako Suzuki,Michael R. Torkzad,Soichi Tanaka,G. Palmer,Johan Lindholm,Torbjörn Holm,Lennart Blomqvist +6 more
TL;DR: Appropriate MR imaging protocols enable more accurate local staging of locally advanced rectal tumors with less number of sequences and without intravenous gadolinium contrast agents.
Journal ArticleDOI
MRI after preoperative radiotherapy for rectal cancer; correlation with histopathology and the role of volumetry
Michael R. Torkzad,Johan Lindholm,Anna Martling,Björn Cedermark,Björn Cedermark,Bengt Glimelius,Lennart Blomqvist +6 more
TL;DR: Volumetry seems to correlate with ypT-stage after preoperative radiotherapy for resectable rectal cancer, and the value of a second MRI after Radotherapy for assessment of distance to CRM and yp t-staging is, however, not apparent.
Journal ArticleDOI
Tumor markers carcinoembryonic antigen, CA 50, and CA 19-9 and squamous cell carcinoma of the esophagus. Pretreatment screening.
TL;DR: Raised CEA levels were found significantly more frequently in intrathoracically localized tumors than in cervical cancers, and patients surviving less than 6 months showed a higher rate of elevated CEA assays than those who survived 6 to 18 months.